EUDA
EUDA Health Holdings Ltd
$15.84
+2.46%
$46.3M
No data for this timeframe.
Vol
Market Cap$46.3M
Cap SizeNano Cap
Press Releases3
Recent Activity
Jun 1, 2026
other
EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask
<p><strong>SINGAPORE, June 01, 2026 (GLOBE NEWSWIRE) -- </strong>EUDA Health Holdings Limited (NA
Apr 28, 2026
Press
EUDA Health announced that its partner Shenzhen Inno Immune received government approval for a TCR-T cell therapy R&D pr
Impact 3/10
Mar 19, 2026
Press
EUDA Health Holdings Ltd announced a 1-for-20 reverse stock split effective March 23, 2026, reducing its outstanding sha
Impact 4/10
Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$55.00 (Mar 2026)
Current $15.84
Low $55.00
Median $55.00
High $55.00
1 analysts
$55.00
$55.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 9, 2026 | Greenridge Global | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $1.60 ▼ -52.9% | $1.60 — $1.60 | 208% YoY | 1 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
NEUTRAL
3/10
EUDA Health announced that its partner Shenzhen Inno Immune received government approval for a TCR-T
Apr 28, 2026
NEUTRAL
4/10
EUDA Health Holdings Ltd announced a 1-for-20 reverse stock split effective March 23, 2026, reducing
Mar 19, 2026
NEUTRAL
4/10
EUDA Health Holdings repurchased and canceled a warrant previously issued to Streeterville Capital f
Mar 4, 2026
Historical analyst distribution (last covering-analyst action Mar 2026): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$55.00 mean target (Mar 2026)
$55.00 Low
$55.00 High
| Metric | Value |
|---|---|
| Current Price | $15.84 |
| Target Low | $55.00 |
| Target Mean | $55.00 |
| Target Median | $55.00 |
| Target High | $55.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$1.60 | $1.60 | $1.60 | 208.1% | -52.9% | 0↑ 1↓ | $0.0B | 299.3% | 1 |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 9, 2026 | Greenridge Global | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 1, 2026
other
EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask
<p><strong>SINGAPORE, June 01, 2026 (GLOBE NEWSWIRE) -- </strong>EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore
Jun 1, 2026
other
EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency
<p align="justify">Singapore, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”), a Singapore-based non-inva
Apr 28, 2026
announcement
EUDA Highlights Shenzhen Inno’s Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development
<p><b>SINGAPORE, April 28, 2026 (GLOBE NEWSWIRE) -- </b> EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based no
Apr 27, 2026
other
EUDA Health Holdings Limited Has Received Notice from Nasdaq that it has Failed to Maintain a Minimum Market Value of its Listed Securities
<p align="justify">Singapore, April 27, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice
Apr 23, 2026
short_volume
Short Volume: EUDA — 56.4% short (1.2M / 2.2M)
Short: 1,219,516 | Exempt: 15,131 | TRF Vol: 2,164,111 | Short Ratio: 56.4% | Off-exchange volume (dark pool + OTC)
Mar 19, 2026
announcement
EUDA Announces Reverse Stock Split of its Ordinary Shares
<p align="justify">SINGAPORE, March 19, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore
Mar 4, 2026
contract
EUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville Warrant
<p>SINGAPORE, March 04, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invas